Clinical Scorecard: Disrupting the Supply Chain With Quality and Quantity
At a Glance
| Category | Detail |
|---|---|
| Condition | Medication Supply Shortages |
| Key Mechanisms | Rigorous quality standards, innovative compounding, rapid production |
| Target Population | Ophthalmologists and retina specialists |
| Care Setting | Healthcare providers, hospitals, surgical centers, clinics, physician offices |
Key Highlights
- Turbare produces high-quality sterile medications to mitigate shortages.
- Bevacizumab is available in prefilled syringes for intravitreal injection.
- The facility adheres to cGMP and FDA requirements for safety and efficacy.
- Turbare addresses critical unmet needs with antibiotic kits.
- Commitment to customer care and tailored solutions for healthcare partners.
Guideline-Based Recommendations
Diagnosis
- Monitor FDA's list of drug shortages to identify critical needs.
Management
- Utilize compounded medications for off-label treatments in ophthalmology.
Monitoring & Follow-up
- Regularly assess production capabilities and inventory levels.
Risks
- Potential shortages of essential injectable medications can impact patient care.
Patient & Prescribing Data
Patients requiring ophthalmic treatments, particularly for wet AMD and diabetic retinopathy.
Compounded medications like bevacizumab can be trusted for quality and efficacy.
Clinical Best Practices
- Ensure compliance with cGMP and FDA standards in compounding.
- Maintain stringent controls for temperature, humidity, and sterility.
- Engage in market research to anticipate and address medication shortages.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.